ACE-031 trial data from years back still worth a look, what do you think?

Posted by reid_hrv in Research & News - 1 points, 0 comments.

I was reading through older ACE-031 papers the other day, the Phase 1 in postmenopausal women from Acceleron, and it is honestly one of the more interesting myostatin-pathway results I have seen. Single dose, clear lean mass bump on MRI versus placebo, and the mechanism of soaking up multiple ligands at once (myostatin, activin, GDF-11) makes sense on paper. I keep wondering why it stalled out for muscular dystrophy when the biology seemed to track.

For me, the nosebleeds and gum bleeding they reported are a real flag though. If a decoy receptor is hitting TGF-B family ligands broadly, that vascular signaling is probably not a small side effect to brush off. Compare that to follistatin 344, which is more targeted but has its own short half life and almost no long term human data. YK-11 is a whole different category and I would not lump it in personally.

Has anyone followed what happened to the soluble ActRIIB approach after 2017? Curious if there is any newer trial, or if the whole strategy got shelved because of those mucosal side effects.

Community discussion - research and educational context only. Not medical advice.